Total Tumor Volume on18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with225 Ac-PSMA-I&T

Total Tumor Volume on18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with225 Ac-PSMA-I&T

Background: PSMA-based alpha therapy using225Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of177 Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therapy outcomes and play...

Full description

Bibliographic Details
Main Authors: Albert, N.L (Author), Bartenstein, P. (Author), Beyer, L. (Author), Brendel, M. (Author), Casuscelli, J. (Author), Cyran, C.C (Author), Gildehaus, F.J (Author), Herlemann, A. (Author), Holzgreve, A. (Author), Ilhan, H. (Author), Kunte, S.C (Author), Kunz, W.G (Author), Ricke, J. (Author), Schmidt-Hegemann, N.-S (Author), Sheikh, G.T (Author), Stief, C.G (Author), Todica, A. (Author), Unterrainer, L.M (Author), Unterrainer, M. (Author), Wenter, V. (Author), Zacherl, M.J (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
225 Ac-PSMA
mCRPC
PSMA PET/CT
total tumor volume
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items